Silicon Investor - Eli Lilly

[zax] LLY (Pre-market) 1,088.50 +84.78 (+8.45%) Eli Lilly Surges 9% After Obliteratin...

zax — 2/4/2026 8:44:41 AM

LLY (Pre-market) 1,088.50 +84.78 (+8.45%)

Eli Lilly Surges 9% After Obliterating Forecasts As Mounjaro, Zepbound Sales Double

investors.com

Eli Lilly (LLY) stock surged early Wednesday after the company reported adjusted earnings of $7.54 per share on $19.29 billion in fourth-quarter sales.

On average, analysts polled by FactSet expected Lilly to earn $6.91 per share on $17.94 billion in sales. In the year-earlier period, Eli Lilly reported $5.32 earnings per share and $13.53 billion in sales.

Diabetes drug Mounjaro brought in $7.41 billion in sales, while weight-loss shot Zepbound generated $4.26 billion. Sales of both more than doubled year over year. Analysts called for a respective $6.6 billion and $3.85 billion.

For the year, Lilly guided to earnings of $33.50 to $35 per share and $80 billion to $83 billion in sales. The Street projected earnings of $33.04 per share and $77.64 billion in sales.

In premarket trades on today's stock market, Eli Lilly stock jumped more than 9% to 1,094.26. Shares tumbled below their 50-day moving average on Tuesday after Novo Nordisk ( NVO) said it expects 2026 sales and operating profit to fall, MarketSurge shows.

Lilly is set to gap back above its 50-day moving average and break a downtrend in an emerging base, offering an aggressive entry. LLY stock also could top the Jan. 22 high of 1,095.48, serving as another early buy point.

[zax] Ozempic is changing how we spend money and time, plus what we eat washingtonpo...

zax — 12/1/2025 9:25:38 AM

Ozempic is changing how we spend money and time, plus what we eat

washingtonpost.com

Industry insiders are gearing up for weight-loss drugs to shake up the consumer economy as they seep into every sector — including apparel, restaurants, grocery, gyms and travel. They are causing a “psychological shift” for the people taking them, said Ali Furman, a partner in PwC’s U.S. consumer markets division. As their bodies change, she said, so are their decisions on how to spend their time and money.

In just over a year, the percentage of U.S. adults taking drugs such as Ozempic, Wegovy, Mounjaro and Zepbound more than doubled to 12.4 percent, according to Gallup. The survey also reported that the obesity rate fell from almost 40 percent in 2022 to 37 percent in 2025. Some companies are already responding by acquiring health food brands, renovating hotel gyms and changing lunch menus. But that’s only scratching the surface, said Diana Melencio, a partner at XRC Ventures, an early stage venture capital firm.

“It's revolutionary,” she said. “GLP-1s will play a huge role in society.”

Pharmacies

The drugs come with some uncomfortable or harmful side effects, including indigestion, nausea and loss of hair and muscle mass. As a result, sales for supplements and vitamin-rich beauty products have surged. Some studies suggest that the medication might also boost fertility.Purchases of pregnancy test kits among a cohort of GLP-1 users surged 148 percent over the course of one year, according NielsenIQ (NIQ).

Supplements

Electrolyte supplements, hair-growth products and anti-nausea medications have skyrocketed among GLP-1 users. Some brands are marketing new product lines aimed at consumers on the medications, and industry experts expect more companies to jump in. There are risks, however, of some supplement companies making misleading claims of replicating GLP-1 shots. “The U.S. has pretty loose standards when it comes to the vitamins, minerals and supplements sector,” Melencio said.

Grocery stores

With the elimination of “food noise,” which can lead to bingeing and distracting thoughts about eating, GLP-1 users are cutting back on snacks and spending more on healthy items.

Compared to non-GLP-1 households, GLP-1 users reduced their spending by 10 percent over a year across 100 categories including groceries, quick-service restaurants and tobacco, according to the data company Numerator. While the fallout could hurt the snack food industry, some companies are innovating and acquiring health food brands. They’re focused on high-protein items, which support muscle mass, are highly satiating and boost metabolism, as well as quick-and-healthy frozen meals.

</snip> Read the rest here: washingtonpost.com

[zax] Eli Lilly’s tirzepatide-based drugs, Mounjaro and Zepbound, when combined have ...

zax — 11/27/2025 11:59:44 AM

Eli Lilly’s tirzepatide-based drugs, Mounjaro and Zepbound, when combined have brought in roughly $25 billion through the first nine months of the year, making it the world’s top-selling medication.

Ozempic 2.0 is on the way, and it could be even more transformative

A new weight loss pill could come within months, and other experimental treatments with more potency are not far behind.

washingtonpost.com

Ozempic, and the class of weight loss drugs it has come to embody, has left its imprint seemingly everywhere: On the lives of millions of patients who’ve lost unprecedented amounts of weight. On grocery store shelves with new offerings explicitly catering to those taking the drugs. Even in the calculations of insurance companies studying the drugs’ effects on mortality. (Yes, there are Ozempic guides to Thanksgiving.)

For all the societal changes ushered in by GLP-1 drugs, their lofty price tags limit who can afford them. Many patients stop taking the medications after experiencing undesirable side effects. Others who could benefit have stayed on the sidelines because they don’t want to jab themselves.

A new wave of the medicine is coming that could be even more transformativefor human health: pills, more potent injectables and new compounds that might have fewer side effects or could be taken just once a month.

“With this newer generation of medications, we’re not just focusing on weight loss,” said David Lau, an endocrinologist and professor emeritus at the University of Calgary Cumming School of Medicine. “We’re talking about changes beyond what you see on the scale.”

Whether these next-generation treatments live up to that promise isn’t assured. They haven’t yet been approved by the Food and Drug Administration, which has warned consumers about unauthorized versions advertised on the internet. And it is common for the FDA to identify new risks after approving drugs, as it has done in recent years with the current GLP-1 blockbusters.

Such is the potential of these future offerings that Eli Lilly, by some measures the most dominant company in the weight loss field, reached a stock market value on Friday exceeding $1 trillion — the first company in the health care sector to hit that milestone.

Here is a look at what’s ahead, with analysis from obesity researchers who have led key clinical trials and who also have received fees from pharmaceutical companies related to their work.

Next-generation pills
Novo Nordisk and Eli Lilly are both preparing to launch once-a-day weight loss pills by next year if the FDA approves them, as is widely expected. That would allow patients to avoid the jab of auto-injector pens with tiny needles.

“Some people are afraid of using needles and giving themselves injections,” Lau said.

Pills don’t require refrigeration — which adds cost and complexity to shipping and storing injectable medications — and there are signs that their price tags will be lower.

“What Henry Ford did with the car wasn’t to make a better car. He just made more of them and made them more accessible,” said Sean Wharton, a physician-researcher in Toronto and the lead author of two New England Journal of Medicine papers on oral GLP-1 drugs published in September. By offering more convenience at a lower cost, he said, these pills could do something similar for weight loss.

</snip> Read the rest here: washingtonpost.com

[zax] LLY 974.41 (+5.44%)

zax — 11/10/2025 10:30:44 AM

[zax] Obesity Drugs May Drop to as Little as $150 a Month President Trump announced ...

zax — 11/6/2025 12:31:56 PM

Obesity Drugs May Drop to as Little as $150 a Month

President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patients who pay with their own money.

nytimes.com

President Trump on Thursday announced a deal that could significantly expand access for millions of Americans to hugely popular obesity drugs by reducing the price to as little as $150 a month.

The Trump administration’s agreements with the drugmakers Novo Nordisk and Eli Lilly would save consumers and the government considerable money on Wegovy, Zepbound and two obesity pills that are expected to win regulatory approval in the coming months.

The lowest price, of $150 a month, will be available only for the lowest doses of the pill form of the drugs. When those drugs reach the market, Medicare and Medicaid will pay that price, as will Americans using their own money to buy the pills directly from manufacturers.

The deal also broadens coverage of the injectable drugs for people on Medicare and Medicaid, the federal insurance programs for older people and those with lower incomes, and lowers the prices the government pays in those programs. Those measures are likely to expand access but still will stop far short of covering all of the millions of people with obesity under those federal programs.

The announcement comes amid a record-long government shutdown over disagreements in Congress over health care costs. Democrats have been withholding their votes on a government spending bill unless Republicans agree to extend subsidies that help Americans by Obamacare insurance.

Mr. Trump, who has long decried the high costs of prescription drugs, has announced a series of deals with drugmakers to lower their cash prices and commit to expanded manufacturing in the United States in exchange for exemptions from high tariffs. The deal on the diabetes and obesity medicines is likely to have the largest consumer impact, given the popularity of the drugs and the large number of Americans who already pay for them out-of-pocket.

Officials said that within the next few months, Americans would be able to use their own money to buy Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound — which are both taken as injections — directly from manufacturers for an average of $350 a month, depending on the dose. The officials said they expected the average to fall to $245 over the next two years.

... nytimes.com

[zax] LLY 953.03 +5.1% Eli Lilly (LLY) to Build $3 Billion European Plant to Manufac...

zax — 11/5/2025 12:50:52 PM

LLY 953.03 +5.1%

Eli Lilly (LLY) to Build $3 Billion European Plant to Manufacture Weight-Loss Pill

tipranks.com

U.S. pharmaceutical company Eli Lilly LLY +5.08% ? has announced plans to build a $3 billion manufacturing plant in the Netherlands as it prepares to produce its highly-anticipated weight-loss pill Orforglipron.

The Dutch plant is the latest investment Eli Lilly is making in the production of Orforglipron, which the company expects to receive regulatory approval in the second half of 2026. The pill is expected to be a game changer for weight-loss medications, which are currently taken by injection.

Orforglipron is also expected to help Eli Lilly cement its lead over Danish rival Novo Nordisk NVO -2.09% ? in the red-hot obesity treatment market. Eli Lilly said the new Dutch facility will make the weight-loss pill for the European market and help strengthen its global supply chains.

Advanced Technologies

The manufacturing plant in the Netherlands will be equipped with advanced technologies such as paperless manufacturing and artificial intelligence (AI) real-time analytics. The company said the Netherlands was chosen for the manufacturing site partly due to its proximity to the European Medicines Agency as well as the availability of a skilled workforce.

The new plant will be situated in Leiden Bio Science Park in Katwijk, Netherlands, and is expected to create 500 skilled manufacturing jobs and about 1,500 construction positions. Construction on the plant is expected to start in early 2026. News of the Dutch plant comes days after Eli Lilly announced a $1.2 billion expansion of its manufacturing site in Puerto Rico to boost Orforglipron production.

... tipranks.com

[zax] LLY 847.98+4.24% (as we speak) on an absolute earnings blowout! finance.yahoo.c...

zax — 10/30/2025 2:18:44 PM

LLY 847.98 +4.24% (as we speak) on an absolute earnings blowout!

finance.yahoo.com

[zax] LLY moving today. Its been due another run, and the Pfizer settlement seems to ...

zax — 10/1/2025 10:06:38 AM

LLY moving today. Its been due another run, and the Pfizer settlement seems to be helping all of the pharmas. I bought at 719 in April of 2024, sold at 844 in March this year, and bought back in at 737 at the end of August. Zepbound and follow up oral meds in this category will significantly grow the bottom line here, IMO.

[zax] Eli Lilly's Obesity Pill Shows Big Wins In Weight, Blood Sugar And Heart Risk Fa...

zax — 8/26/2025 9:41:41 AM

Eli Lilly's Obesity Pill Shows Big Wins In Weight, Blood Sugar And Heart Risk Factors

finance.yahoo.com

Eli Lilly and Co. (NYSE: LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral orforglipron in adults with obesity or overweight and type 2 diabetes.

In the trial, all three doses of orforglipron met the primary and all key secondary endpoints, delivering significant weight loss, meaningful A1C reductions, and improvements in cardiometabolic risk factors at 72 weeks.

With the completion of ATTAIN-2, Lilly now has the complete clinical data package required to initiate global regulatory submissions for orforglipron.

In the ATTAIN-2 trial, orforglipron met the primary endpoint of superior body weight reduction compared to placebo.

Earlier this month, Eli Lilly stock came under pressure when it released data from Phase 3 ATTAIN-1 trial, showing orforglipron 36 mg lowered weight by an average of 12.4% (27.3 lbs) compared to 0.9% (2.2 lbs) with placebo using the efficacy estimand, below Wall Street’s expectations of around 15%.

Tuesday’s data helped ease some of those concerns, with shares rising nearly 3% in premarket trading.

For the primary endpoint, daily orforglipron 36 mg lowered weight by an average of 10.5% (22.9 lbs) compared to 2.2% (5.1 lbs) with placebo using the efficacy estimand.

In a key secondary endpoint, orforglipron lowered A1C (blood sugar) by 1.3% to 1.8% from a baseline of 8.1% across doses.

In another key secondary endpoint, 75% of participants taking the highest dose of orforglipron achieved an A1C =6.5%, at or below the American Diabetes Association’s definition of diabetes.

Additionally, orforglipron showed clinically meaningful benefits across key cardiovascular risk factors, including non-HDL cholesterol, systolic blood pressure, and triglycerides.

In a pre-specified exploratory analysis, the highest dose of orforglipron reduced high-sensitivity C-reactive protein (hsCRP) levels, a marker of inflammation, by 50.6%.

In the treatment regimen estimand, orforglipron demonstrated statistically significant improvements across both the primary and all key secondary endpoints when compared with placebo.

Participants on orforglipron achieved meaningful reductions in body weight, with average declines of 5.1% at the 6 mg dose, 7.0% at 12 mg, and 9.6% at 36 mg, versus 2.5% for placebo.

The proportion of patients achieving at least a 10% reduction in body weight rose with dosage, reaching 22.6% for 6 mg, 31.2% for 12 mg, and 45.6% for 36 mg, compared with just 9.0% in the placebo group.

Similarly, those achieving weight reductions of at least 15% were 6.8%, 14.4%, and 26.0% across the three dose levels, versus 3.0% on placebo.

Glycemic control also improved markedly, with reductions in A1C of 1.2%, 1.5%, and 1.7% across the 6 mg, 12 mg, and 36 mg groups, compared with 0.5% for placebo.

Among participants, 64.6% (6 mg), 75.9% (12 mg), and 75.5% (36 mg) achieved an A1C level below 7%, versus 30.5% with placebo. Furthermore, 52.5%, 57.6%, and 66.6% of patients in the respective treatment groups reached an A1C of 6.5% or lower, compared with only 15.4% in the placebo arm.

The safety profile of orforglipron in ATTAIN-2 was consistent with the established GLP-1 receptor agonist class. The most commonly reported adverse events were gastrointestinal-related and generally mild-to-moderate in severity.

The most common adverse events for participants treated with orforglipron (6 mg, 12 mg and 36 mg, respectively) were nausea (20.1%, 31.1% and 36.4%) vs. 8.4% with placebo, vomiting (12.8%, 20.2% and 23.1%) vs. 3.8%, diarrhea (21.3%, 24.8% and 27.4%) vs. 15.0%, constipation (17.7%, 21.1% and 22.4%) vs. 7.8%, and dyspepsia (9.1%, 15.4% and 10.9%) vs. 3.5%.

Treatment discontinuation rates due to adverse events were 6.1% (6 mg), 10.6% (12 mg), and 10.6% (36 mg) for orforglipron vs. 4.6% with placebo.

Price Action: LLY stock is trading higher by 2.72% to $714.22 premarket at last check Tuesday.

finance.yahoo.com

[zax] LLY 862.08 +19.90 (+2.71%) 10:30 AM Eli Lilly Jumps, Reversing Its Weight-L...

zax — 2/6/2025 10:36:36 AM

LLY 862.08 +19.90 (+2.71%) 10:30 AM

Eli Lilly Jumps, Reversing Its Weight-Loss Setback, On A Strong 2025 Outlook

investors.com

Eli Lilly ( LLY) stock reversed higher Thursday on its upbeat outlook despite lighter-than-expected fourth-quarter sales of its well-known weight-loss and diabetes drugs.

During the fourth quarter, obesity treatment Zepbound brought in $1.91 billion in sales, while type 2 diabetes drug Mounjaro generated $3.53 billion. That lined up with Lilly's preannouncement last month, but missed more bullish analyst calls for $1.99 billion and $3.63 billion, respectively.

The company noted continued strong demand for the Mounjaro, but the drug faced "lower realized prices due to favorable changes in Q4 2023 to estimates for rebates and discounts."

In morning trades, Eli Lilly stock jumped more than 2% to 859.10. Shares are consolidating with a buy point at 972.53, according to MarketSurge. On Wednesday, Lilly stock closed above its 200-day line for the first time in nearly three months.

Mounjaro, Zepbound Sales Rocket Across all of its products, Eli Lilly's sales surged 45% to $13.53 billion. That just missed forecasts for $13.55 billion, according to FactSet. Adjusted earnings more than doubled, rocketing 114% to $5.32 per share. Earnings handily beat expectations for $5.06 a share.

Despite coming up short, Mounjaro sales rocketed 124% while Zepbound put up a triple-digit gain after launching in the year-earlier period.

But sales of a similar drug, Trulicity, tumbled 26% to $1.25 billion and missed forecasts for $1.34 billion. Trulicity treats type 2 diabetes. Like Mounjaro and Zepbound, it mimics the GLP-1 hormone to help improve feelings of satiety and blood sugar markers.

For 2025, Lilly expects $58 billion to $61 billion in sales and adjusted earnings of $22.50 to $24 per share. The midpoints of Eli Lilly's outlook topped analysts' forecast. The Street projected $58.77 billion in sales and $22.76 earnings per share.

The guidance includes expectations for continued "erosion of Trulicity volumes" and similar growth from last year for its big-name drugs Mounjaro and Zepbound.

[zax] [bluesky] People sometimes make fun of science that sounds stupid and random. ...

zax — 12/20/2024 8:06:15 PM

[bluesky]

People sometimes make fun of science that sounds stupid and random. Meanwhile, a study of lizard saliva turned into a peptide medication, which was turned into a diabetes medication, which was turned into a GLP1 weight loss drug, that just became the first therapy every approved for … sleep apnea
— Derek Thompson (@dkthomp.bsky.social) 2024-12-21T00:41:21.896Z

[/bluesky]

[zax] Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock...

zax — 11/26/2024 3:16:37 PM

Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy?

investors.com

The proposal would increase usage of drugs like Lilly's Zepbound and Novo Nordisk's ( NVO) Wegovy. Today, Medicare doesn't pay for obesity treatments unless they're used for a related condition, like diabetes or reducing the risk of heart attacks or strokes.

But the proposal requires a 60-day comment period, so it will be up President-elect Donald Trump's administration whether it goes into effect. Incoming Secretary of the Department of Health and Human Services, Robert F. Kennedy Jr., has been skeptical about weight-loss drugs. But Dr. Mehmet Oz, who Trump has tapped to lead Medicare, has praised them, according to NBC News.

BMO Capital Markets analyst Evan Seigerman recently said a Kennedy-tied selloff is overdone.

Kennedy "remains limited in his ability to influence either policy or pricing of obesity medications," Seigerman said in a report.

</snip> Read the rest here: investors.com

[zax] +55% YTD. Talk about no-brainers.

zax — 10/15/2024 10:19:20 AM

[zax] BREAKING: FDA approves weight-loss drug Wegovy to reduce heart-disease risks LL...

zax — 3/8/2024 2:45:29 PM

BREAKING: FDA approves weight-loss drug Wegovy to reduce heart-disease risks

LLY

[Glenn Petersen] Eli Lilly’s direct drug sales alone may not upend the industry, but others could...

Glenn Petersen — 1/5/2024 8:11:04 PM

Eli Lilly’s direct drug sales alone may not upend the industry, but others could follow suit

PUBLISHED FRI, JAN 5 20242:37 PM EST
UPDATED 5 HOURS AGO
Annika Kim Constantino @ANNIKAKIMC
CNBC.com

KEY POINTS

Eli Lilly is shaking up the pharmaceutical industry with a new website offering telehealth prescriptions and direct home delivery of certain drugs, such as weight loss treatments, to expand patient access.
The company’s direct-to-consumer push won’t necessarily upend the pharmaceutical industry and the traditional prescription drug supply chain, according to some analysts.
But other drugmakers could follow suit with their own direct-to-consumer models and add pressure on what critics call a complex pharmaceutical industry.

Eli Lilly is shaking up the pharmaceutical industry with a new website offering telehealth prescriptions and direct home delivery of certain drugs, including its red-hot weight loss treatment Zepbound, to expand patient access.

The company’s direct-to-consumer push announced Thursday, the first of its kind for a big drugmaker, won’t necessarily upend the pharmaceutical industry and the prescription drug supply chain alone, according to some analysts.

But other drugmakers could follow suit with their own direct-to-consumer models, according to some analysts. That could add more pressure on what many critics call a complex system for distributing, pricing and prescribing drugs in the U.S. — a structure they say has led to higher prices and fewer choices for patients.

“There’s always a possibility for disruption. I think you should never rule out any sort of disruption,” BMO Capital Markets analyst Evan Seigerman told CNBC. “I don’t think that is necessarily happening tomorrow, but I think that you should never assume that things can’t change.”

Lilly’s new platform comes as other companies move to disrupt the drug system in some way, in part as they face more political pressure to cut consumer costs and increase pricing transparency.

Those actions come as lawmakers target drug supply chain middlemen in new legislation and as the Biden administration takes its own steps to rein in prices of medications, such as by giving Medicare the power to negotiate down drug prices for the first time in its six-decade history.

Eli Lilly said its new effort — dubbed LillyDirect — aims to increase access to medicines for chronic diseases, including the highly popular weight loss drugs.

Those treatments, which have soared in demand over the last year as they help patients shed unwanted pounds, are plagued by supply constraints and concerns about potentially harmful knockoffs. Patients also face long waitlists to meet with obesity medicine specialists who can prescribe the drugs to them, a problem Eli Lilly hopes to address, according to Seigerman.

Eli Lilly’s Zepbound won Food and Drug Administration approval just two months ago, but some analysts say it could garner more than $1 billion in sales in its first year on the market.

LillyDirect won’t significantly disrupt the industry

Eli Lilly’s site eliminates the need for a patient to visit the doctor’s office to get a prescription and, in some cases, for a pharmacy to fill it.

But some analysts said Eli Lilly’s site alone will not significantly threaten the traditional drug distribution system, which involves a multitiered network of manufacturers, drug wholesalers, pharmacies and pharmacy benefit managers, or PBMs.

“I don’t think PBMs and the whole infrastructure that we have are going anywhere,” Seigerman told CNBC. “I think what [Eli Lilly] really did was identify some friction points in getting these products [weight loss drugs] to patients, and they’re coming up with a way to solve for that.”

“From my understanding, it’s just that there’s no retail pharmacy where a patient is having to go hunt for that particular [drug] dose, it’s being shipped right to them,” he said of Eli Lilly’s services.

Eli Lilly’s site connects patients with an independent telehealth provider who can prescribe any FDA-approved weight loss drug or other medications for diabetes and migraines. If the prescribed treatment is Eli Lilly’s, the patient can have a third-party online pharmacy deliver it to their door.

Patients will also receive Eli Lilly’s discounts for drugs if they qualify for the company’s savings-card programs, the company noted in a release. One program allows people with insurance coverage for Zepbound, which costs more than $1,000 per month, to pay as little as $25 out-of-pocket. Meanwhile, those whose insurance does not cover the drug may be able to pay as low as $550.

Some experts view that transparent pricing as a shot across the bow to PBMs, the largest of which are owned by CVS, UnitedHealth Group and Cigna.

Drugmakers have long complained that they give PBMs steep drug discounts in exchange for higher placement on a formulary — an insurance plan’s list of preferred medications — only for those middlemen to not pass along savings to patients.

But Eli Lilly’s savings-card program and new site won’t cut PBMs out of the equation.

“If you still use your health insurance to get these drugs through [Eli Lilly’s] website, it’s still going to get processed by a PBM,” Jeff Jonas, a Gabelli Funds portfolio manager, told CNBC.

Patients who get drugs such as Zepbound from Eli Lilly’s site can choose to pay with cash to avoid PBMs altogether. But Bernstein analysts said in a Thursday note that they expect the “vast majority” of potential weight loss drug users to get medications through insurance.

Other drugmakers could follow Eli Lilly

More pharmaceutical companies could adopt a similar approach to Eli Lilly’s.

Cantor Fitzgerald analyst Louise Chen said drugmakers could benefit the most from using a direct-to-consumer pharmacy model for high-selling drugs.

“Cause of the scale of your effort, it [would] probably make sense for bigger drugs,” Chen wrote in an email to CNBC. “You get more bang for the buck and you are reaching more people.”

But Chen said it may be more difficult for a drugmaker to pursue a direct-to-consumer model with smaller, more specialized drugs, such as treatments for complex, chronic, or rare medical conditions. For example, some drugs require specialized training for administration, such as injecting or infusing a therapy into a patient’s vein through an IV.

Drugmakers that do adopt a direct-to-consumer approach could add even more pressure on the nation’s traditional drug supply chain after other companies moved to simplify the system in recent months.

That includes CVS Health, which announced plans to overhaul its business model for pricing prescription drugs in December, adopting a model similar to billionaire Mark Cuban’s direct-to-consumer pharmacy, Cost Plus Drugs. Health-care giant Cigna also announced in November that its PBM will offer a pricing model similar to Cuban’s venture.

Cost Plus Drugs aims to drive down the price of medicines broadly by selling them at a set 15% markup over their cost, plus pharmacy fees.

That company is already shaking up the broader health-care industry: CVS suffered a blow over the summer when a major California health insurer, Blue Shield of California, announced it will no longer use the company as its PBM and instead will partner with several other businesses, including Cuban’s firm and Amazon Pharmacy.

Eli Lilly weight loss drug site may not upend industry (cnbc.com)

[Glenn Petersen] FDA approves Eli Lilly’s tirzepatide for weight loss, paving way for wider use o...

Glenn Petersen — 11/10/2023 7:52:41 AM

FDA approves Eli Lilly’s tirzepatide for weight loss, paving way for wider use of blockbuster drug

PUBLISHED WED, NOV 8 202312:20 PM EST
UPDATED WED, NOV 8 20238:00 PM EST
Annika Kim Constantino @ANNIKAKIMC
CNBC.com

KEY POINTS

The Food and Drug Administration approved Eli Lilly’s tirzepatide drug for weight loss, paving the way for even wider use of the blockbuster medication.
The active ingredient in the drug, tirzepatide, has already been approved for the treatment of Type 2 diabetes under the name Mounjaro since May 2022.
But the FDA’s new approval means adults who have obesity or are overweight with at least one weight-related condition can use the drug, which will be marketed as Zepbound, for chronic weight management.

Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.
Cristina Arias | Cover | Getty Images

The Food and Drug Administration on Wednesday approved Eli Lilly’s blockbuster drug tirzepatide for weight loss, paving the way for even wider use of the treatment in the U.S.

The active ingredient in the drug, tirzepatide, has already been approved for the treatment of Type 2 diabetes under the name Mounjaro since May 2022.

But the FDA’s new approval means adults who have obesity or are overweight with at least one weight-related condition can use the drug, which will be marketed as Zepbound, for chronic weight management.

Zepbound should be available in the U.S. by the end of the year, and will carry a list price of about $1,060 for a month’s supply, according to a release from Eli Lilly.

Before Wednesday’s approval, many patients had used tirzepatide off-label for weight loss, adding to a frenzy of demand for treatments that can help patients shed pounds, such as Novo Nordisk’s Wegovy and Ozempic. All three drugs have faced supply constraints for months due to soaring demand.

The weight lossapproval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding obesity drug market, which Wall Street analysts believe could grow to a $100 billion industry by 2030. The increased use of drugs has raised questions about how the changes will affect an array of industries — though it may be too early to tell how many people will use them.

The approval also comes as obesity affects an estimated 650 million adults globally, and roughly 40% of the adult population in the U.S.

“Obesity and overweight are serious conditions that can be associated with some of the leading causes of death such as heart disease, stroke and diabetes,” said Dr. John Sharretts, director of the division of diabetes, lipid disorders, and obesity in the FDA’s Center for Drug Evaluation and Research. “In light of increasing rates of both obesity and overweight in the United States, today’s approval addresses an unmet medical need.”

How well Zepbound works

Zepbound is an injection administered once weekly, and the dosage must be increased over four to 20 weeks to achieve the target dose sizes of 5, 10 or 15 milligrams per week.

The drug works by activating two naturally produced hormones in the body: glucagon-like peptide-1, known as GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP.

The combination is said to slow the emptying of the stomach, making people feel full for longer and suppressing appetite by slowing hunger signals in the brain.

The FDA said the approval was based on two of Eli Lilly’s late-stage trials on tirzepatide, which evaluated its effects on weight loss after 72 weeks.

In a late-stage study of more than 2,500 adults with obesity but not diabetes, those taking 5 milligrams of tirzepatide for 72 weeks lost about 16% of their body weight on average. Higher doses of the drug were associated with even more weight loss, with a 15-milligram dose leading to 22.5% weight loss on average.

Another late-stage study found that tirzepatide caused up to 15.7% weight loss among people who are obese or overweight and have Type 2 diabetes.

Pricing, supply constraints

Still, access to tirzepatide and other diabetes and obesity treatments remains a big challenge.

The list price of tirzepatide for weight loss is $1,059.87 per month for six different dose sizes, which is about 20% lower than that of Wegovy, Eli Lilly said in a press release. The company noted that the amount a patient pays out of pocket will likely be less if they have insurance.

Eli Lilly also said it is launching a commercial savings card program to expand access to Zepbound, which could allow people with insurance coverage for the drug to pay as low as $25 for a one-month or three-month prescription. Meanwhile, those whose insurance does not cover Zepbound may be able to pay as low as $550 for those prescriptions.

“Broader access to these medicines is critical, which is why Lilly is committed to working with healthcare, government and industry partners to ensure people who may benefit from Zepbound can access it,” said Mike Mason, executive vice president and president of Eli Lilly Diabetes and Obesity, in a statement.

The bigger issue is that many insurance companies are dropping weight loss drugs from their plans. Those insurers cite the extreme costs of covering those medications, and some say they want to see more data demonstrating the health benefits of the drugs beyond losing weight.

Preliminary data is already available: A recent late-stage trial found that Novo Nordisk’s weight loss drug Wegovy reduced the risk of cardiovascular events such as heart attack and stroke by 20%. The results suggest that Wegovy and similar drugs like Mounjaro could have long-lasting heart health benefits.

It is unclear whether Zepbound will eventually encounter supply issues after the U.S. saw widespread shortages of Mounjaro.

On Wednesday, Eli Lilly CEO David Ricks told reporters that the company is prepared to fully launch Zepbound and has the supply to do so. He also noted that all doses of Mounjaro are now listed as available on the FDA’s drug shortage website.

The company is working to boost production capacity for tirzepatide, Ricks added.

“We’re prepared for a big bold launch here toward the end of the year and we’ll work hard to continue to expand our supply capacity to meet the needs of people with obesity,” Ricks told reporters.

Zepbound side effects
Similar to other weight loss drugs, Zepbound is associated with side effects such as nausea, diarrhea, vomiting, constipation, abdominal discomfort and pain, fatigue and allergic reactions, among others, according to the FDA’s approval label.

The agency also noted that Zepbound causes thyroid C-cell tumors in rats, but it’s unclear if the drug has that effect in humans.

The FDA advises against the use of Zepbound in patients with a personal or family history of medullary thyroid cancer – a cancer that forms inside your thyroid gland – or in people with a rare condition called Multiple Endocrine Neoplasia syndrome type 2.

The agency also said that Zepbound should not be used in combination with Mounjaro or another weight loss or diabetes drug targeting GLP-1 because “the safety and effectiveness of coadministration” has not been established.

The agency’s other warnings about Zepbound include inflammation of the pancreas, gallbladder problems, acute kidney injury and suicidal behavior or thinking.

“Anti-obesity medications in the past have been associated with suicidal ideation, and that’s really something that should be watched for when you’re treating somebody for weight loss,” Dr. Leonard Glass, Eli Lilly’s senior vice president of global medical affairs for diabetes and obesity, said during a call with reporters. “Therefore we encourage people to keep an eye on this and go to their health care provider for any side effects, they can be monitored.”

FDA approves Eli Lilly drug tirzepatide for weight loss (cnbc.com)

[Glenn Petersen] As drugmakers race to develop the next big weight loss pill, Eli Lilly may have ...

Glenn Petersen — 6/28/2023 10:48:08 AM

As drugmakers race to develop the next big weight loss pill, Eli Lilly may have an edge

PUBLISHED WED, JUN 28 20239:35 AM EDT
UPDATED 28 MIN AGO
Annika Kim Constantino @ANNIKAKIMC
CNBC.com

KEY POINTS

-- Drugmakers are jockeying to capitalize on the next major innovation coming to the blockbuster weight loss industry.

-- For now, one experimental oral drug from Eli Lilly appears to have an edge over pills from Novo Nordisk and Pfizer – even though it may not win U.S. approval first.

--,Eli Lilly’s orforglipron appears to be the top contender due to its strong efficacy data and convenience as a once-daily pill without dietary restrictions.

-- But pivotal data from several pharmaceutical companies is slated to come out later this year and pricing of all the major drugs is still uncertain.

Drugmakers are jockeying to capitalize on the next major innovation coming to the blockbuster weight loss industry: effective, convenient and potentially affordable obesity pills.

An estimated 40% of U.S. adults are obese, making a successful pill a massive opportunity.

It’s too early to crown a winner, especially since pivotal data from several pharmaceutical companies is slated to come out later this year. And there’s still the all-important question of pricing to come down for the major players.

But for now, one experimental oral drug from Eli Lilly appears to have an edge over pills from Novo Nordisk and Pfizer – even though it may not win U.S. approval first.

All three manufacturers are developing oral versions of GLP-1s, a class of drug that mimics a hormone produced in the gut to suppress a person’s appetite. Novo Nordisk’s popular Wegovy and Ozempic treatments, which sparked a weight loss industry gold rush last year, are weekly GLP-1 injections also known as semaglutide.

The pills are easier to manufacture than injections, which come in the form of single-use pens. That means the oral drugs could potentially help alleviate the supply shortages plaguing their injectable counterparts.

Pills are also typically cheaper than injections, though it’s unclear if that will be the case with the obesity pills.

Wegovy’s list price tops $1,300 per monthly package, and Ozempic’s is about $935. Novo Nordisk has a low-dose oral version of semaglutide that has the same list price as Ozempic for a monthly package of 30 tablets. That pill, marketed as Rybelsus, is only approved for Type 2 diabetes.

None of the three drugmakers have provided estimates for how much the new obesity pills would cost.

Novo Nordisk has one important advantage: The Danish company has already released phase three clinical trial results for its high-dose version of oral semaglutide, which is intended for weight management, and told CNBC it expects to file for Food and Drug Administration approval later this year.

Eli Lilly is still in the middle of phase three clinical trials on its oral drug, orforglipron, meaning it’s likely to hit the market later.

Still, analysts are confident in the competitive edge of orforglipron in the long run, especially after Eli Lilly unveiled phase two clinical trial results last week that showcased the drug’s strong efficacy profile.

Strong efficacy profile

According to Eli Lilly’s phase two results, overweight or obese patients who took 45 milligrams of orforglipron once a day lost up to 14.7% of their body weight after 36 weeks. That compares with 2.3% weight loss for people who received a placebo.

Eli Lilly’s results appear consistent with the weight reduction caused by Novo Nordisk’s pill, but were achieved over a shorter trial period.

Overweight or obese patients who took 50 milligrams of Novo Nordisk’s drug once a day saw an average weight loss of 15.1% after 68 weeks, according to phase three clinical trial results released Sunday.

Bank of America analyst Geoff Meacham said in a Sunday research note that Eli Lilly’s available orforglipron data “compares quite favorably” to Novo Nordisk’s oral semaglutide, “cross trial comparison caveats aside.”

Cantor Fitzgerald analyst Louise Chen told CNBC that orforglipron could potentially achieve an even greater level of weight loss over a longer trial period.

“The more you use these drugs, the more weight loss you’ll see until it plateaus, right?” Chen said. “So the thought is, if you’re getting pretty close to semaglutide’s weight loss in almost roughly half the time with orforglipron, you will probably exceed it.”

Chen said the hope is that orforglipron leads to similar reduction as Eli Lilly’s injection tirzepatide, which resulted in weight loss of around 22% after 72 weeks.

The company’s phase three clinical trials on orforglipron will study the drug over longer time periods.

At least for now, analysts say Eli Lilly’s pill may also have the upper hand over Pfizer’s oral GLP-1, danuglipron, which is still in phase two clinical trials.

Patients with Type 2 diabetes who took a 120-milligram version of danuglipron twice a day lost around 10 pounds on average after 16 weeks, according to results from one phase two clinical trial.

It’s difficult to compare danuglipron’s efficacy to that of other oral GLP-1s due to differing patient populations and the lack of longer-term data on the drug.

A Pfizer spokesperson told CNBC that the company is still studying the drug in further phase two clinical trials and “would also look to have longer data” beyond the 16-week mark in the future.

Ease of use

Wells Fargo analyst Mohit Bansal said in a research note that Pfizer’s danuglipron will be challenged to compete in the oral GLP-1 space given Eli Lilly’s strong orforglipron data.

He added that physicians generally prefer once-daily pills — like orforglipron — over twice-daily drugs like danuglipron.

Health experts seem to agree: “Patient compliance increases a lot if it’s a once-a-day pill, so it’s definitely a big advantage. People often end up missing a few times a week if they have to take something twice a day,” said Dr. John Yoon, an endocrinology professor at UC Davis Health.

Pfizer is developing a once-daily version of danuglipron.

The company on Monday also said it would stop developing another experimental pill, lotiglipron, which Bansal said had been the “more attractive GLP-1” in Pfizer’s portfolio since it’s only taken once a day. Shares of Pfizer fell 5% Monday following that news.

But Pfizer and Eli Lilly do share one key advantage over Novo Nordisk’s oral semaglutide: no dietary restrictions.

Patients need to take Novo Nordisk’s oral semaglutide in the morning on an empty stomach with no more than four ounces of plain water, according to the FDA label for the low-dose, approved version of the drug. They’re instructed to wait 30 minutes before eating, drinking or taking other oral medicines.

That’s because Novo Nordisk’s oral semaglutide is a peptide medication, which is more difficult for the gut to absorb, according to Dr. Eduardo Grunvald, medical director for UC San Diego’s Center for Advanced Weight Management.

“If you take it with food or drink, it just won’t get absorbed efficiently,” Grunvald told CNBC.

He said pills from Eli Lilly and Pfizer are non-peptide GLP-1s, which are absorbed more easily and don’t require dietary restrictions.

Cantor Fitzgerald’s Chen said market research suggests that those restrictions are a “big negative for patients,” making the pills from Eli Lilly and Pfizer convenient alternatives.

Overall, Eli Lilly’s orforglipron appears to be the top contender in the weight loss pill space due to its strong efficacy data and convenience as a once-daily pill without dietary restrictions.

But Chen emphasized that the data unveiled later this year could potentially change that: “Save some room for the new data coming.”

For health experts like Grunvald, naming a winner in the oral weight loss drug space is less important.

“I think these oral GLP-1s mean having more tools in our toolbox, having more options for different people who might react differently to different medicines,” he said. “That’s really the future of this all.”

Eli Lilly weight loss pill may best Pfizer, Novo Nordisk drugs (cnbc.com)

[JamesK] Really nice move in LLY. Moves aren't as strong but similar chart patterns in AZ...

JamesK — 4/9/2022 1:45:09 PM

Really nice move in LLY. Moves aren't as strong but similar chart patterns in AZN MRK and big bios like AMGN VRTX REGN.

Maybe with the FED slamming on the brakes there is rotation into less economically sensitive areas.

Might feel bad losing some of your stock but be happy you're getting good prices. Sometimes I buy back the options and sell new ones in your situation.

[Lance Bredvold] I don't know about anyone else, but I just don't believe prices and PE's just ke...

Lance Bredvold — 4/8/2022 9:15:38 PM

I don't know about anyone else, but I just don't believe prices and PE's just keep going up forever. The Jan 270 expired nicely but the July 280 is far underwater and an additional Oct 300 is also looking pretty dumb at the moment. Yet getting over $20 for each one feels pretty good for a while at least and I think I'll have the courage to sell a $320 whenever I can get $25 or so for them.

[Lance Bredvold] I have a 270 call sold for January and during the pop this week sold another at ...

Lance Bredvold — 12/17/2021 11:51:41 AM

I have a 270 call sold for January and during the pop this week sold another at $280 for July. While the news has been good and I have actually penciled in EPS of $8.20 (above the $7.95 speculated 2 posts ago) that puts my $270 call at a PE of nearly 33. That's more than the company has shown as a high for any of the last 10 years except 2021. Clearly $280 is just as pricy so I'm feeling pretty secure in my sales which were both for $22.00. Of course I could be wrong, but I think the odds are excellent that I'll profit from these sales.

If I had some of my shares in retirement accounts I'd probably sell as it bounced so high the other day, but I don't want to claim the huge gain on the shares in my taxable accounts at this time, so a nice 8% bonus is welcome though it also entails some tax expense.

[Moonray] Eli Lilly Pops On Boosted 2021 Outlook As Covid Brings In $2.1 Billion o~~~ O

Moonray — 12/15/2021 10:22:09 AM

[Moonray] Eli Lilly and Company Expected to Earn FY2021 Earnings of $7.95 Per Share (NYSE...

Moonray — 12/11/2021 10:38:39 AM

Eli Lilly and Company Expected to Earn FY2021
Earnings of $7.95 Per Share (NYSE:LLY)

o~~~ O

[Moonray] Cramer’s lightning round: I like Eli Lilly over Biogen and Cassava Sciences o~~...

Moonray — 11/16/2021 10:42:20 PM

Cramer’s lightning round: I like Eli Lilly over Biogen and Cassava Sciences

o~~~ O

[Moonray] Eli Lilly CEO: There will be enough COVID-19 vaccine for 'entire world' by next...

Moonray — 6/17/2021 1:07:24 PM

Eli Lilly CEO: There will be enough COVID-19
vaccine for 'entire world' by next summer

o~~~ O

[Moonray] Eli Lilly and Company— The biopharmaceutical stock jumped 13% after the approva...

Moonray — 6/7/2021 4:05:48 PM

Eli Lilly and Company — The biopharmaceutical stock jumped 13%
after the approval of Biogen’s Alzheimer’s medicine by the FDA.
Eli Lilly is developing its own drug to treat Alzheimer’s.

It is quite bullish to see the P&F Objective more than 100 points higher.

o~~~ O

[Moonray] Distribution of Eli Lilly COVID-19 therapy paused in 8 states over variant conc...

Moonray — 6/1/2021 9:27:56 PM

Distribution of Eli Lilly COVID-19 therapy
paused in 8 states over variant concerns

For now, the FDA recommends using
Regeneron's antibody cocktail instead.

Federal health authorities have paused distribution
of Eli Lilly's monoclonal antibody cocktail in eight
tates over COVID-19 variant efficacy concerns.

The COVID-19 treatment will halt distribution in
Arizona,
alifornia,
Florida,
llinois,
Indiana,
Massachusetts,
Oregon and
Washington
"until further notice" due to variants' elevation in those
states, the U.S. Department of Health and Human
Services and Assistant Secretary for Preparedness
and Response announced in a bulletin this week.

More at: abcnews.go.com

o~~~ O

[Moonray] Eli Lilly gets Indian emergency use nod for Covid-19 antibody drug combination ...

Moonray — 6/1/2021 9:20:34 PM

Eli Lilly gets Indian emergency use nod for Covid-19 antibody drug combination

The company said it is in talks with the Indian government and regulatory authorities to donate the drugs to help speed up access and provide more treatment options for Covid-19

Eli Lilly and Co's antibody drug combination has received an emergency use approval in India for the treatment of mild-to-moderate Covid-19, bolstering the country's arsenal of medicines to tackle a devastating second wave of the pandemic.

A combination of the U.S. drugmaker's monoclonal antibodies bamlanivimab and etesevimab has been given approval for restricted use in emergency situations in hospital settings in adults, the company's Indian unit said in an emailed statement.

More at: kathmandupost.com

o~~~ O

[Moonray] EXCLUSIVE U.S. opens criminal probe into alleged lapses at Eli Lilly plant The...

Moonray — 6/1/2021 9:07:44 PM

EXCLUSIVE U.S. opens criminal probe into alleged lapses at Eli Lilly plant

The U.S. Justice Department has launched a criminal investigation into Eli Lilly and Co (LLY.N)focused on alleged manufacturing irregularities and records tampering at a factory in Branchburg, New Jersey, that produces the pharmaceutical giant’s COVID-19 therapy and other drugs, three people familiar with the matter said.

The probe represents a significant escalation of the government scrutiny on Lilly. The pharmaceutical company, one of the world's largest, has been under examination for more than a year by the U.S. Food and Drug Administration over alleged manufacturing and records violations at the Branchburg factory.

Reuters questioned Lilly about the criminal inquiry on Wednesday. On Thursday morning, the company disclosed in a securities filing that it had received a subpoena from the Justice Department in May seeking documents related to the Branchburg factory.

The company did not disclose anything more about the nature or focus of the investigation and said it was cooperating fully in the matter.

More at: reuters.com

o~~~ O

[Moonray] Lilly Announces Global Donations of COVID Treatments By Wes Mills, May 4th 2021 ...

Moonray — 5/4/2021 3:30:51 PM

Lilly Announces Global Donations of COVID Treatments
By Wes Mills, May 4th 2021

INDIANAPOLIS - Indianapolis-based Eli Lilly and Co. (NYSE: LLY)
says it will donate an unspecified amount of its COVID-19 therapies
to low and lower-middle-income countries most heavily affected by
the pandemic. The company says it will donate both baricitinib as
well as its cocktail prescription of bamlanivimab and etesevimab,
which provides options to treat COVID-19 patients at different stages
of the disease.

The announcement comes as the company also says it will provide
400,000 doses of baricitinib to the Indian government for COVID-19
patients who are hospitalized.

The World Health Organization reported Tuesday that India recorded
nearly 360,000 new cases of the disease over the past 24 hours

Lilly Chairman and Chief Executive Officer David Ricks says even
as the world makes progress on vaccine rollouts, it remains vital for
treatments to be made available.

“Bamlanivimab with etesevimab together reduces the risk of hos-
pitalizations and death for high-risk patients in the outpatient setting,
while recent data show baricitinib in addition to current standard of
care reduces death in hospitalized patients,” said Ricks.

Lilly says it will work with global humanitarian nonprofit Direct Relief
to allocate the treatments. The initiative will begin immediately.

The company says the allocation will be based on the disease burden
and hospitalization rates in each country.

o~~~ O

[Moonray] Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guid...

Moonray — 4/27/2021 8:46:52 AM

Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance

Eli Lilly Misses Earnings Forecast, Lowers Full-Year Profit Guidance

Eli Lilly shares slide 5% premarket as earnings fall short of estimates and guidance lags consensus

Eli Lilly profit misses as vaccines sap U.S. demand for COVID-19 drugs

o~~~ O

[Moonray] Lilly says U.S. government modified purchases of its COVID-19 antibody treatmen...

Moonray — 4/12/2021 1:18:56 PM

Lilly says U.S. government modified purchases
of its COVID-19 antibody treatments
By Jaimy Lee - April 12, 2021

Shares of Eli Lilly & Co. LLY, -1.14% were up 0.3% in premarket trading on Monday after the company said the U.S. government modified purchase agreements for its COVID-19 antibody therapies. The agreement for bamlanivimab, which was the first Lilly antibody treatment to receive emergency authorization, now includes etesevimab. Using a combination of the two antibody therapies is more effective against some of the new virus variants that have emerged. Lilly said the new agreement terminates the original purchase agreement for bamlanivimab and in effect cancels the roughly 350,000 doses of bamlanivimab that had been scheduled for delivery in March. Lilly's stock has gained 9.2% since the start of the year, while the S&P 500 SPX, -0.07% has gained 9.9%.

o~~~ O

[Moonray] Pfizer And Eli Lilly's Osteoarthritis Drug Rejected By FDA Panel As Too Risky o...

Moonray — 3/26/2021 12:49:21 PM

Pfizer And Eli Lilly's Osteoarthritis Drug Rejected By FDA Panel As Too Risky

o~~~ O

[Moonray] US government stops distribution of Eli Lilly Covid-19 antibody treatment due t...

Moonray — 3/26/2021 12:48:02 PM

US government stops distribution of Eli Lilly Covid-19
antibody treatment due to spread of coronavirus variants

o~~~ O

[Moonray] .Eli Lilly's combo therapy for COVID-19 cuts serious illness and death in large...

Moonray — 3/10/2021 12:20:44 PM

.Eli Lilly's combo therapy for COVID-19 cuts
serious illness and death in large study.

o~~~ O

[Moonray] U.S. buys 100,000 courses of Eli Lilly’s latest antibody treatment Sara Salina...

Moonray — 2/26/2021 11:13:48 AM

U.S. buys 100,000 courses of Eli Lilly’s latest antibody treatment
Sara Salinas

The United States has agreed to purchase 100,000 treatment courses
of Eli Lilly’s recently approved antibody treatment for Covid-19.

The agreement comes at an initial purchase price of $210 million and
includes an option to buy additional supply as needed, up to 1.2 million
total treatment courses.

The therapeutic from Eli Lilly combines two monoclonal antibodies,
bamlanivimab and etesevimab, administered through an IV infusion
to treat high-risk Covid patients who are displaying symptoms but
have not yet developed severe disease.

It received an emergency use authorization from the Food and Drug
Administration earlier this month.

o~~~ O

[Moonray] Eli Lilly profit benefits from successful launch of Covid antibody treatment M...

Moonray — 1/29/2021 10:51:08 AM

Eli Lilly profit benefits from successful
launch of Covid antibody treatment
Melodie Warner

Eli Lilly's fourth-quarter profit beat Wall Street estimates, thanks
in part to strong demand for its diabetes and cancer drugs and
sales of its Covid-19 antibody treatment, Reuters reported.

Eli Lilly’s new COVID-19 treatment helped the drugmaker’s
fourth-quarter profit surge even though U.S. regulators approved
its use late in the quarter.

The antibody treatment bamlanivimab brought in $850 million
in U.S. sales for Lilly after the Food and Drug Administration
authorized emergency use in November for patients with
mild-to-moderate COVID-19.

The company's overall sales rose 21.7% to $7.44 billion.

Excluding items, Eli Lilly earned $2.75 per share, beating
estimates of $2.35 per share.

o~~~ O

[Moonray] Eli Lilly teams up with pharma rival GSK and partner Vir for COVID-19 antibody ...

Moonray — 1/27/2021 10:24:55 AM

Eli Lilly teams up with pharma rival GSK and
partner Vir for COVID-19 antibody cocktail test

COVID-19 has been a real leveler in competitor terms;
once warring Big Pharmas have joined forces for the
greater good on vaccines, both in R&D and more recently
on production, and now on treatments.

Today, Lilly penned a deal with GlaxoSmithKline and biotech
partner Vir to wed the former’s emergency-cleared COVID-19
antibody bamlanivimab 700 mg with GSK/Vir’s experimental
therapy VIR-7831 (aka GSK4182136) 500 mg.

The hope is that in the so-called Blaze-4 trial, which has been
expanded to accommodate this combo, will see the two
neutralizing antibodies that bind to different epitopes of the
SARS-CoV-2 spike protein create better potency and make
the virus less likely to evade, especially with new variants.

More at: Eli Lilly teams up with pharma rival GSK
and partner Vir for COVID-19 antibody cocktail test

o~~~ O

[Moonray] Eli Lilly's COVID-19 treatment shows 70% drop in hospitalizations o~~~ O

Moonray — 1/27/2021 10:14:59 AM

[Moonray] Monoclonal antibody treatment by Eli Lilly found to cut risk of serious COVID-1...

Moonray — 1/21/2021 9:46:21 AM

Monoclonal antibody treatment by Eli Lilly found
to cut risk of serious COVID-19, drugmaker reports
Karen Weintraub, USA TODAY, Jan 21, 2021

A drug developed by Eli Lilly and Company dramatically
reduced the risk of developing symptomatic COVID-19
among nursing home residents, the company found.

Of 299 residents, half of whom received a placebo, those
randomized to receive the drug bamlanivimab had up to
an 80% lower risk of contracting COVID-19, according to
a study that has not yet been published.

More at: usatoday.com

o~~~ O

[Moonray] Eli Lilly CEO says Covid variant from South Africa may ‘evade’ its antibody dru...

Moonray — 1/12/2021 12:13:25 PM

Eli Lilly CEO says Covid variant from
South Africa may ‘evade’ its antibody drug
Kevin Stankiewicz

Eli Lilly CEO Dave Ricks told CNBC the company is not sure whether its Covid-19 antibody drugs will be effective against a coronavirus strain initially found in South Africa. However, he expressed confidence that the treatment would work on the variant found in the U.K.

“The South African variant ... is the one of concern. It has more dramatic mutations to that spike protein, which is the target” of these antibody drugs, Ricks said on “Squawk Box.” “Theoretically, it could evade our medicines.”

He said the company wants to work with the Food and Drug Administration on a plan to adapt antibody therapies to virus variants, including the one first discovered in South Africa.

“We actually have a large library of these antibodies now that are sitting pre-clinically,” said Ricks. “We could think about a very expedited path to study them in maybe a month or two, and then authorize their use. That would seem to be a smart thing to do as this virus mutates.”

o~~~ O

[Moonray] Eli Lilly ...

Moonray — 1/11/2021 12:09:25 PM

Eli Lilly up 20% after Donanemab shows phase 2 positive result for Alzheimer's disease

Don't Chase Eli Lilly For Its Alzheimer's Drug

Eli Lilly says its Alzheimer's drug slows the rate of decline in a mid-stage trial

o~~~ O

[Moonray] Dialysis clinics provide new path for delivery of stockpiled COVID-19 antibody ...

Moonray — 12/30/2020 9:59:12 AM

Dialysis clinics provide new path for delivery
of stockpiled COVID-19 antibody drugs in U.S.

Dialysis centers in the United States are rolling out COVID-19
antibody treatments this week, a new path for delivery of Eli Lilly
and Regeneron drugs approved for emergency use but facing
skepticism and logistical problems in some hospitals.

Supplies of the drugs are piling up as hospitals grapple with
overflowing wards and mass vaccinations. Kidney dialysis
patients are among those most at risk from COVID-19,
which is especially deadly among people with chronic
illnesses.

More at: nationalpost.com

o~~~ O

[Moonray] Lilly Announces Agreement to Acquire Prevail Therapeutics Acquisition will est...

Moonray — 12/15/2020 12:29:47 PM

Lilly Announces Agreement to Acquire Prevail Therapeutics

Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disease

INDIANAPOLIS and NEW YORK, Dec. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 million) payable at closing plus one non-tradable contingent value right ("CVR") worth up to $4.00 per share in cash (or an aggregate of approximately $160 million), for a total consideration of up to $26.50 per share in cash (or an aggregate of approximately $1.040 billion). The CVR is payable (subject to certain terms and conditions) upon the first regulatory approval of a product from Prevail's pipeline as set forth in more detail below. Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases.

The acquisition will establish a new modality for drug discovery and development at Lilly, extending Lilly's research efforts through the creation of a gene therapy program that will be anchored by Prevail's portfolio of clinical-stage and preclinical neuroscience assets. Prevail's lead gene therapies in clinical development are PR001 for patients with Parkinson's disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD) and PR006 for patients with frontotemporal dementia with GRN mutations (FTD-GRN). Prevail's preclinical pipeline includes PR004 for patients with specific synucleinopathies, as well as potential gene therapies for Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders.

"Gene therapy is a promising approach with the potential to deliver transformative treatments for patients with neurodegenerative diseases such as Parkinson's, Gaucher and dementia," said Mark Mintun, M.D., vice president of pain and neurodegeneration research at Lilly. "The acquisition of Prevail will bring critical technology and highly skilled teams to complement our existing expertise at Lilly, as we build a new gene therapy program anchored by well-researched assets. We look forward to completing the proposed acquisition and working with Prevail to advance their groundbreaking work through clinical development."

"Lilly is an established leader in neuroscience drug development and commercialization who shares our commitment to patients with neurodegenerative diseases, and I'm excited for Prevail to join the Lilly family," said Asa Abeliovich, M.D., Ph.D., founder and chief executive officer of Prevail. "I'm incredibly proud of the Prevail team, who have made great progress advancing our pipeline of gene therapy programs for patients with these devastating disorders. In just over three years, Prevail has advanced two first-in-class gene therapy programs into clinical development for PD-GBA, nGD, and FTD-GRN, established two manufacturing platforms, and developed a broad pipeline with great potential to impact patients in need of disease-modifying treatment options. With its global scale and resources, Lilly will be the ideal organization to maximize the potential of our pipeline and accelerate our ability to bring these therapies to as many patients as possible. We look forward to working together to advance our shared mission."

Under the terms of the agreement, Lilly will commence a tender offer to acquire all outstanding shares of Prevail Therapeutics Inc. for a purchase price of $22.50 per share in cash (or an aggregate of approximately $880 million) payable at closing plus one non-tradeable CVR. The CVR entitles Prevail stockholders to up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable (subject to certain terms and conditions) upon the first regulatory approval for commercial sale of a Prevail product in one of the following countries: United States, Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 centsper month until December 1, 2028 (at which point the CVR will expire). There can be no assurance any payments will be made with respect to the CVR. The transaction is not subject to any financing condition and is expected to close in the first quarter of 2021, subject to customary closing conditions, including receipt of required regulatory approvals and the tender of a majority of the outstanding shares of Prevail's common stock. Following the successful closing of the tender offer, Lilly will acquire any shares of Prevail that are not tendered in the tender offer through a second-step merger at the same consideration as paid in the tender offer.

The purchase price payable at closing represents a premium of approximately 117 percent to the 60-day volume-weighted average trading price of Prevail's common stock ended on December 14, 2020, the last trading day before the announcement of the transaction. Prevail's Board of Directors unanimously recommends that Prevail's stockholders tender their shares in the tender offer. Additionally, certain Prevail stockholders, beneficially owning approximately 51 percent of Prevail's outstanding common stock, have (subject to certain terms and conditions) agreed to tender their shares in the tender offer.

Upon closing, the impact of this transaction will be reflected in Lilly's 2021 financial results according to Generally Accepted Accounting Principles (GAAP). There will be no change required to Lilly's 2021 financial guidance being issued today for research and development expense or non-GAAP earnings per share as a result of this transaction.

For Lilly, Lazard is acting as sole financial advisor and Weil, Gotshal & Manges LLP is acting as legal counsel. For Prevail, Centerview Partners LLC is acting as sole financial advisor, Ropes & Gray LLP is acting as legal counsel, and Cooley LLP also provided legal counsel.

Prevail Therapeutics Pipeline

PR001 is being developed as a potentially disease-modifying, single-dose AAV9-based gene therapy for patients with Parkinson's disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD), delivered by intra-cisterna magna injection. The PROPEL trial, a Phase 1/2 clinical trial of PR001 for the treatment of PD-GBA patients, is ongoing. The PROVIDE trial, a Phase 1/2 clinical trial of PR001 for the treatment of Type 2 Gaucher disease patients, is now recruiting. The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for PR001 for the treatment of PD-GBA and for the treatment of nGD. It has also granted Orphan Drug Designation for PR001 for the treatment of Gaucher disease, and Rare Pediatric Disease Designation for the treatment of nGD. PR006 is being developed as a potentially disease-modifying, single-dose AAV9-based gene therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN), also delivered by intra-cisterna magna injection. The PROCLAIM trial, a Phase 1/2 clinical trial of PR006 for the treatment of FTD-GRN patients, is currently ongoing and the first patient was dosed in December 2020. The FDA and the European Commission have granted orphan designation for PR006 for the treatment of FTD, and the FDA has granted Fast Track Designation for PR006 for FTD-GRN. PR004 is a gene therapy in preclinical development for patients with certain synucleinopathies. PR004 utilizes an AAV9 vector to deliver the GBA1 gene, which encodes glucocerebrosidase (GCase), and a molecule that suppresses expression of a-Synuclein. Prevail is developing a broad pipeline of additional AAV gene therapies for the treatment of Alzheimer's disease, ALS, Parkinson's disease, and other neurodegenerative disorders. Preclinical development of these potential therapies is currently ongoing.

About Prevail Therapeutics
Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. Prevail is developing PR001 for patients with Parkinson's disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD); PR006 for patients with frontotemporal dementia with GRN mutations (FTD-GRN); and PR004 for patients with certain synucleinopathies.

Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort with The Silverstein Foundation for Parkinson's with GBA, and OrbiMed, and is headquartered in New York, NY.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com. C-LLY

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements about Lilly's proposed acquisition of Prevail Therapeutics Inc. ("Prevail"), regarding potential contingent consideration amounts and terms, regarding the anticipated occurrence, manner and timing of closing of the proposed transaction, regarding Prevail's product candidates and ongoing preclinical development, regarding Lilly's development of a potential gene therapy program, and regarding Lilly's expected 2021 financial guidance and the impact of the proposed acquisition on research and development expense and non-GAAP earnings per share. It reflects current beliefs and expectations; however, as with any such undertaking, there are substantial risks and uncertainties in consummating the proposed transaction, in drug research, development and commercialization, and in Lilly's evaluation of its estimated financial results for 2021 and the impact of the proposed acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that the proposed transaction will be completed in the anticipated timeframe or at all, that the conditions required to complete the proposed transaction will be met, that Lilly will realize the expected benefits of the proposed transaction, that product candidates will be approved on anticipated timelines or at all, that Lilly will be successful in building a gene therapy program, that any products, if approved, will be commercially successful, that all or any of the contingent consideration will become payable on the terms described herein or at all, that Lilly's financial results will be consistent with its expected 2021 guidance or that Lilly can reliably predict the impact of the proposed acquisition on its 2021 financial guidance and results. For further discussion of these and other risks and uncertainties, see Lilly's and Prevail's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission (the "SEC"). Except as required by law, neither Prevail nor Lilly undertakes any duty to update forward-looking statements to reflect events after the date of this press release.

Additional Information about the Acquisition and Where to Find It
The tender offer for the outstanding shares of Prevail referenced in this communication has not yet commenced. This announcement is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Prevail, nor is it a substitute for the tender offer materials that Lilly and its acquisition subsidiary will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, Lilly and its acquisition subsidiary will file tender offer materials on Schedule TO, and thereafter Prevail will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION. HOLDERS OF SHARES OF PREVAIL ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF PREVAIL SHARES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of shares of Prevail at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC's web site at www.sec.gov.

In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Lilly and Prevail file annual, quarterly and special reports and other information with the SEC. You may read and copy any reports or other information filed by Lilly or Prevail at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the Commission at 1-800-SEC-0330 for further information on the public reference room. Lilly's and Prevail's filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

Refer to:	Mark Taylor; mark.taylor@lilly.com; (317) 276-5795 (Lilly Media)
	Kevin Hern; hern_kevin_r@lilly.com; (317) 277-1838 (Lilly Investors)
	Gina Nugent; gina@tenbridgecommunications.com; (617)460-3579 (Prevail Media)
	investors@prevailtherapeutics.com; (Prevail Investors)

SOURCE Eli Lilly and Company

o~~~ O

[Moonray] INDIANAPOLIS, Dec. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)...

Moonray — 12/15/2020 12:21:55 PM

INDIANAPOLIS, Dec. 15, 2020 /PRNewswire/ --

Eli Lilly and Company (NYSE: LLY) today announced its 2021 financial guidance, highlighted by volume-based revenue growth, increased investment in research and development, operating margin expansion and strong earnings performance. The company also revised certain elements of its 2020 financial guidance and reviewed potential key events for the upcoming year, including important data readouts for several investigational medicines in its clinical pipeline and the possibility of multiple regulatory submissions and approvals.

The company's 2020 and 2021 financial guidance are being provided on both a reported and a non-GAAP basis. Reported guidance is presented in accordance with U.S. generally accepted accounting principles (GAAP). Non-GAAP measures reflect adjustments for the items described in the associated reconciliation tables. The non-GAAP measures are presented to provide additional insights into the underlying trends in the company's business.

Josh Smiley, Lilly's chief financial officer, outlined the company's near-term growth prospects and provided 2021 financial guidance. "We're pleased with our performance despite the unprecedented challenges facing the world in 2020. We expect 2021 to be another exciting year for Lilly, characterized by robust volume-driven revenue growth for our key medicines, while we continue to invest in and progress our pipeline, expand operating margins and deliver impressive EPS and cash flow growth. Reflecting this growth, we have announced a 15 percent increase in our dividend for 2021. One year after we outlined our high-level outlook through 2025, we are increasingly confident in our ability to deliver top-tier revenue growth and operating margin percent expansion into the mid-to-high 30s during this timeframe."

Commenting on the company's cash flow expectations, Smiley added, "We expect to deliver strong cash flow in 2021, which we will continue to deploy thoughtfully across our capital allocation priorities. We remain focused on funding our existing marketed products, new launches, lifecycle opportunities and replenishing our pipeline. We will continue to leverage bolt-on acquisitions and licensing opportunities to augment our future growth prospects with external innovation. Finally, we plan to return cash to shareholders through an increased dividend and our ongoing share repurchase program, while maintaining strong investment grade ratings."

"Lilly is in the midst of an exciting period of prolonged growth for the company, driven by an expanding portfolio of new medicines focused on diabetes, oncology, immunology, and neuroscience," said David A. Ricks, Lilly's chairman and chief executive officer. "We enter 2021 emboldened by the lessons we have learned during the COVID-19 pandemic, the agility and persistence we have displayed, and the knowledge that we are supported by one of the fastest growing portfolios in the industry. With more exciting data readouts and innovation prospects on the way, we have a remarkable opportunity to make life better for many more patients who can benefit from Lilly medicines."

2020 Financial Guidance

The company has updated certain elements of its 2020 financial guidance. On a reported basis, earnings per share for 2020 are now expected to be in the range of $6.28 to $6.48. On a non-GAAP basis, earnings per share for 2020 are now expected to be in the range of $7.45 to $7.65.

Revenue for 2020 is now expected to be in the range of $24.2 billion to $24.7 billion, reflecting expectations of increased bamlanivimab sales due to an additional purchase agreement with the U.S. government.

Gross margin as a percent of revenue is still expected to be approximately 78 percent on a reported basis and is now expected to be approximately 79 percent on a non-GAAP basis, reflecting expectations of increased bamlanivimab sales.

Marketing, selling and administrative expenses are still expected to be in the range of $6.0 billionto $6.1 billion. Research and development expenses are still expected to be in the range of $5.8 billion to $5.9 billion.

Operating margin, defined as operating income as a percent of revenue, is still expected to be approximately 25 percent on a reported basis, and is now expected to be approximately 30 percent on a non-GAAP basis.Other income (expense) is now expected to be income in the range of $600 million to $700 million, reflecting additional projected gains on investments in equity securities. The market valuations for these securities could fluctuate significantly throughout the remainder of the year, with current valuations placing other income (expense) above the revised 2020 guidance range.

The 2020 effective tax rate is still expected to be approximately 14 percent on both a reported basis and a non-GAAP basis.

o~~~ O

[Moonray] Lilly Announces 2021 Financial Guidance, Updates 2020 Guidance- Lilly expects t...

Moonray — 12/15/2020 12:15:55 PM

Lilly Announces 2021 Financial Guidance, Updates 2020 Guidance-

Lilly expects to deliver strong financial and operational performance in 2021, highlighted by volume-based revenue growth, operating margin expansion, pipeline advancements and solid cash flow.

- 2021 revenue is expected to be between $26.5 billion and $28.0 billion, driven by volume growth from key growth products, including Trulicity, Taltz, Verzenio, Jardiance, Olumiant, Cyramza, Emgality, Tyvyt, and Retevmo, as well as an estimated $1 billion to $2 billion of revenue from COVID-19 therapies.

- Operating margin is expected to be approximately 30 percent on a reported basis and approximately 32 percent on a non-GAAP basis in 2021.

- Earnings per share (EPS) for 2021 are expected to be in the range of $7.25 to $7.90 on a reported basis and $7.75 to $8.40 on a non-GAAP basis.

- Continued pipeline progress in 2021 will include a number of Phase 3 data readouts for important investigational medicines and new indications, the initiation of several new Phase 3 clinical trials, and the possibility of multiple regulatory submissions and approvals.

- For 2020, the company now expects revenue to be between $24.2 billion and $24.7 billion, and earnings per share to be in the range of $6.28 to $6.48 on a reported basis and $7.45 to $7.65 on a non-GAAP basis.

o~~~ O

[Moonray] Lilly Announces 15 Percent Dividend Increase Dec 14, 2020, 16:05 ET INDIANAPOL...

Moonray — 12/15/2020 12:11:14 PM

Lilly Announces 15 Percent Dividend Increase
Dec 14, 2020, 16:05 ET

INDIANAPOLIS, Dec. 14, 2020 /PRNewswire/ --
The board of directors of Eli Lilly and Company (NYSE: LLY) today
announced a 15 percent increase in its quarterly dividend.

The dividend for the first quarter of 2021 will be $0.85 per share on
outstanding common stock. This raises the annual indicated rate to
$3.40 per share.

The dividend is payable March 10, 2021, to shareholders of record
as of the close of business on February 12, 2021.

o~~~ O

[Moonray] Lilly's COVID-19 Antibody Drug Gets FDA Emergency Use Authorization For Non-hos...

Moonray — 11/9/2020 11:38:24 PM

Lilly's COVID-19 Antibody Drug Gets FDA Emergency
Use Authorization For Non-hospitalized Patients

o~~~ O

[Moonray] Eli Lilly wins US$375mln US government order for COVID-19 drug The drug can hel...

Moonray — 10/28/2020 12:48:09 PM

Eli Lilly wins US$375mln US government order for COVID-19 drug

The drug can help stop those with only mild to moderate symptoms
from becoming dangerously ill, believes the company

More at: proactiveinvestors.co.uk

o~~~ O

[Moonray] Eli Lilly misses third-quarter estimates on Covid drug development costs Melodi...

Moonray — 10/27/2020 12:30:59 PM

Eli Lilly misses third-quarter estimates
on Covid drug development costs
Melodie Warner

Eli Lilly’s third-quarter profit fell short of analysts’ expectations
due to increased costs from developing Covid-19 treatments
and lower demand for some of its medicines, Reuters reported.

Lilly estimated its 2020 Covid-19 research and development
expense at roughly $400 million. Total third-quarter operating
expenses increased 9% to $3.04 billion.

Net income fell 4% to $1.21 billion, or $1.33 per share, in the
quarter ended Sept. 30. Third quarter, revenue rose 5% to
$5.74 billion but fell short of the average estimate of $5.88 billion.

o~~~ O

[Moonray] Lilly antibody drug fails in a Covid-19 study; others go on Message 33004930 o~...

Moonray — 10/27/2020 10:12:29 AM

Lilly antibody drug fails in a Covid-19 study; others go on
Message 33004930

o~~~ O